Your browser is no longer supported. Please, upgrade your browser.
MACK Merrimack Pharmaceuticals, Inc. daily Stock Chart
Merrimack Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.11 Insider Own0.60% Shs Outstand130.59M Perf Week16.38%
Market Cap176.29M Forward P/E- EPS next Y-0.65 Insider Trans-0.50% Shs Float125.28M Perf Month-42.31%
Income-142.00M PEG- EPS next Q-0.14 Inst Own61.40% Short Float18.70% Perf Quarter-34.07%
Sales123.00M P/S1.43 EPS this Y8.90% Inst Trans-21.28% Short Ratio6.24 Perf Half Y-54.69%
Book/sh-2.11 P/B- EPS next Y-20.40% ROA-136.60% Target Price3.00 Perf Year-67.57%
Cash/sh- P/C- EPS next 5Y5.60% ROE59.90% 52W Range1.13 - 4.62 Perf YTD-51.36%
Dividend- P/FCF- EPS past 5Y-5.70% ROI322.00% 52W High-70.77% Beta1.95
Dividend %- Quick Ratio- Sales past 5Y33.40% Gross Margin95.00% 52W Low19.47% ATR0.15
Employees294 Current Ratio0.40 Sales Q/Q- Oper. Margin- RSI (14)37.72 Volatility13.22% 11.95%
OptionableYes Debt/Eq- EPS Q/Q31.90% Profit Margin- Rel Volume1.16 Prev Close1.46
ShortableYes LT Debt/Eq- EarningsMay 10 BMO Payout- Avg Volume3.75M Price1.35
Recom3.00 SMA20-11.99% SMA50-32.04% SMA200-50.48% Volume4,367,760 Change-7.53%
Oct-07-16Downgrade JP Morgan Overweight → Neutral
May-27-16Initiated Robert W. Baird Neutral $8
Dec-23-15Reiterated Mizuho Buy $16 → $13
Oct-27-15Reiterated Oppenheimer Outperform $13 → $15
Apr-21-15Reiterated Mizuho Buy $13 → $16
Oct-10-14Resumed Oppenheimer Outperform $9 → $11
Jul-08-14Resumed Brean Capital Buy $16
Jun-20-14Reiterated Oppenheimer Outperform $10 → $8.50
Aug-09-13Reiterated Oppenheimer Outperform $12 → $10
Jun-25-13Initiated Mizuho Buy $12
May-08-12Initiated Oppenheimer Outperform $12
Jun-22-17 08:00AM  Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Moleculin Biotech and Merrimack Pharmaceuticals Accesswire +11.45%
Jun-21-17 03:43PM  These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop? Motley Fool
Jun-20-17 10:33AM  Merrimack Completes Enrollment in Phase II Study for MM-141 Zacks +6.72%
Jun-19-17 06:55AM  Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018 PR Newswire
Jun-14-17 04:24AM  Why Is Merrimack (MACK) Down 57.6% Since the Last Earnings Report? Zacks -5.93%
Jun-08-17 06:55AM  Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources PR Newswire +8.63%
May-31-17 04:55PM  Why iRobot, Golar LNG, and Merrimack Pharmaceuticals Slumped Today Motley Fool -23.26%
10:58AM  Why Merrimack Pharmaceuticals Stock Is Tanking Today Motley Fool
May-25-17 04:30PM  Merrimack Announces Management Change PR Newswire
May-16-17 05:11AM  Edited Transcript of MACK earnings conference call or presentation 10-May-17 12:30pm GMT Thomson Reuters StreetEvents -6.38%
May-11-17 10:25AM  Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde Zacks
08:30AM  Edited Transcript of MACK earnings conference call or presentation 10-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-10-17 08:19AM  Merrimack's (MACK) Reports Wider-than-Expected Q1 Loss Zacks +5.92%
08:00AM  Investor Network: Merrimack Pharmaceuticals, Inc. to Host Earnings Call Accesswire
06:52AM  Merrimack reports 1Q loss Associated Press
06:45AM  Merrimack Reports First Quarter 2017 Financial Results PR Newswire
May-02-17 04:30PM  Merrimack Announces Timing of First Quarter 2017 Investor Conference Call PR Newswire
Apr-27-17 12:03PM  What's in the Cards for Merrimack (MACK) in Q1 Earnings? Zacks
Apr-19-17 03:07PM  Merrimack Pharmaceuticals, Inc. Value Analysis (NASDAQ:MACK) : April 19, 2017 Capital Cube
Apr-18-17 08:32AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : April 18, 2017 Capital Cube
Apr-17-17 07:00AM  Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research PR Newswire
Apr-05-17 04:05PM  Merrimack Declares $140M Special Dividend in Connection with Recently Completed Asset Sale PR Newswire
Apr-04-17 08:05AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : April 4, 2017 Capital Cube
Apr-03-17 11:30AM  Merrimack Launches as New, Refocused Research & Clinical Development Company with Resources to Advance Prioritized Lead Pipeline Candidates MM-121, MM-141 and MM-310 PR Newswire
Mar-31-17 08:58AM  Are Options Traders Betting on a Big Move in Merrimack (MACK) Stock? Zacks
Mar-30-17 12:11PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
12:00PM  Merrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion PR Newswire
Mar-27-17 07:00AM  Merrimack to Present at the 2017 American Association for Cancer Research Annual Meeting PR Newswire
Mar-24-17 02:45PM  Merrimack (MACK) Starts Enrollment in Solid Tumors Study Zacks
Mar-23-17 01:20PM  Merrimack asset sale prompts legal blowback at
01:20PM  Merrimack asset sale prompts legal blowback American City Business Journals
07:00AM  Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors PR Newswire
Mar-22-17 05:50AM  Lawyer: former Merrimack employee accused of insider trading to fight charges at
Mar-15-17 09:35AM  Merrimack Pharmaceuticals, Inc. :MACK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017
Mar-14-17 03:02PM  Merrimack Pharmaceuticals, Inc. :MACK-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-08-17 09:30AM  Biotech's Fall as President Trump to Address Pricing Concerns: Today's Research Reports on Arena Pharmaceuticals and Merrimack Pharmaceuticals Accesswire
Mar-07-17 01:04PM  MERRIMACK PHARMACEUTICALS INC Financials -5.26%
Mar-02-17 05:08PM  Merrimack (MACK) Q4 Loss Lower than Expected, Revenues Top
01:21PM  These 5 Stocks Under $10 Could Explode Up Soon
Mar-01-17 11:50AM  Edited Transcript of MACK earnings conference call or presentation 1-Mar-17 1:30pm GMT
09:59AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
08:58AM  Merrimack's (MACK) Q4 Loss In-Line With Estimates
07:20AM  Merrimack reports 4Q loss
07:07AM  Q4 2016 Merrimack Pharmaceuticals Inc Earnings Release - Before Market Open
07:00AM  Merrimack Reports Fourth Quarter and Full-Year 2016 Financial Results PR Newswire
Feb-22-17 04:05PM  Merrimack Announces Timing of Fourth Quarter 2016 Investor Conference Call PR Newswire
Feb-17-17 03:09PM  Merrimack (MACK): What Awaits the Stock in Q4 Earnings?
Feb-12-17 08:41AM  Is Merrimack Pharmaceuticals Worth Stashing in Portfolios? at Motley Fool
Feb-11-17 02:04PM  3 Stocks Begging for a Buyout at Motley Fool
Feb-08-17 12:10PM  Merrimack Pharmaceuticals employee arrested, charged with insider trading at
Feb-07-17 06:20PM  Merrimack Pharma employee arrested on U.S. insider trading charge
06:18PM  UPDATE 1-Merrimack Pharma employee arrested on U.S. insider trading charge
06:17PM  Biotech employee arrested, accused by U.S. of insider trading
07:37AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors
Feb-06-17 06:02PM  Why Merrimack Pharmaceuticals Got Crushed 23.8% in January at Motley Fool
Feb-02-17 04:54PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-30-17 04:12PM  Tesaro, AstraZeneca Could Shrink Clovis' Ovarian Cancer Drug Pool
Jan-26-17 09:25AM  Here Are the Biotech Stocks Moving Ahead of the Opening Bell -5.63%
Jan-20-17 04:29PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-18-17 07:30AM  Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO PR Newswire
Jan-17-17 05:13PM  Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?
04:05PM  DryShips, Alcobra Sink into Tuesdays 52-Week Low Club
08:00AM  Merrimack Pharmaceuticals Prospects for the New MACK and Review Accesswire
Jan-12-17 09:30AM  Latest Reports on Diffusion and Merrimack as Drug Stocks are Hit by President Trump's Comments Accesswire
Jan-11-17 04:04PM  Macys, Teva Join Wednesdays 52-Week Low Club
08:50AM  Is the Options Market Predicting a Spike in Merrimack (MACK) Stock?
Jan-10-17 04:04PM  DryShips, Merrimack Pharma Stuck in Tuesdays 52-Week Low Club -7.36%
01:19PM  Merrimack Pharmaceuticals Inc (MACK) Cancer Drugs Sold To Ipsen at Insider Monkey
10:10AM  Company News for January 10, 2017
06:24AM  Here's Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016 at Motley Fool
Jan-09-17 06:34PM  Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B
05:41PM  So the Nasdaq Is At a Historical High but the Dow Is Going Opposite Direction
01:55PM  Merrimack Pharma to Sell Cancer Drugs for $1B at Investopedia
10:42AM  Why Merrimack Pharmaceuticals Stock Is Roaring Higher Today at Motley Fool
10:12AM  McDonald's sells most of its China business; Fiat Chrysler invests big in US; VCA shares are howling on Mars deal
10:05AM  Merrimack Sells Pancreatic Cancer Drug to Ipsen for $1 Billion at TheStreet
09:59AM  Biotech Stocks Surge Monday Amid Flurry of Deal Activity
09:50AM  Mondays 4 Biggest Biopharma Movers
09:17AM  Merrimack Pharmaceuticals' stock soars on heavy volume after drug sale deal at MarketWatch
08:47AM  Stock Futures Mostly Lower as Crude Oil Slides Below $53
08:16AM  The wait for Dow 20K drags on, Apple's iPhone turns 10 and the Detroit Auto Show revs up
07:34AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Costs Associated with E
07:13AM  Merrimack Soars on $1 Billion Sale of Cancer Drugs to Ipsen
12:42AM  France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal Reuters
12:39AM  France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 bln deal Reuters
Jan-08-17 09:30PM  Cambridge's Merrimack to sell key drugs for $575M, slash headcount at
09:06PM  [$$] Merrimack to Sell Onivyde, Generic Doxil to Ipsen at The Wall Street Journal
08:23PM  Ipsen to buy some Merrimack assets for about $1 billion
07:45PM  Merrimack Concludes Strategic Review; Announces Plan to Divest Assets and Sharpen Strategic Focus PR Newswire
Jan-06-17 04:04PM  DryShips, Merrimack Tumble into Fridays 52-Week Low Club -5.26%
Jan-05-17 04:04PM  Dryships, Agile Therapeutics in Thursdays 52-Week Low Club -7.09%
Jan-04-17 04:10PM  Merrimack to Present at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-22-16 06:15PM  Merrimack (MACK) Drops as Breast Cancer Drug Trial Stops
Dec-21-16 05:11PM  Here's Why Merrimack Pharmaceuticals Tumbled 18.4% Today at Motley Fool -18.44%
04:04PM  Merrimack, Fitbit Languish in Wednesdays 52-Week Low Club at 24/7 Wall St.
11:50AM  Merrimack Pharmaceuticals Stops Mid-Stage Breast Cancer Trial
09:55AM  Cambridge-based Merrimack halts cancer drug trial, spurring further stock slide at
09:09AM  Merrimack Shares Crash After Halting Breast Cancer Study
08:55AM  Dow Futures Creep Higher as Index's 20,000 Milestone Is Within Reach
07:40AM  Merrimack Pharmaceuticals' stock plummets after breast cancer treatment trial halted at MarketWatch
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. It offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The company's therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trial for treating patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trial for the treatment of glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trial for treating metastatic breast cancer. Its therapeutic oncology candidates also include MM-302 for treating patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, the company's therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; MM-151 that has completed a Phase I clinical trial for treating solid tumors; and MM-310 for treating solid tumors. Further, it is developing preclinical product candidates for solid tumor indications. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Drummond Daryl CHead of ResearchMay 12Option Exercise2.694,09711,021105,828May 12 05:00 PM
Drummond Daryl CHead of ResearchMay 12Sale3.724,09715,241101,731May 12 05:00 PM
PORTER MICHAEL EDirectorMar 10Option Exercise2.6985,000228,650839,448Mar 13 09:04 PM
Stewart Edward J.Head of CommercialJul 26Option Exercise2.4730,00074,10051,385Jul 27 04:51 PM
Schoeberl Birgit M.Head of DiscoveryJul 25Option Exercise2.1250,000106,000115,657Jul 27 04:48 PM
Schoeberl Birgit M.Head of DiscoveryJul 25Sale5.5050,000275,00065,657Jul 27 04:48 PM